Results 151 to 160 of about 97,766 (255)

Ownership changes in the pharmaceutical industry: understanding the 2023 pharma mergers and acquisitions landscape of Europe. [PDF]

J Pharm Policy Pract
Fabian D, Wild C.
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Human vaccines and immunotherapeutics: News September 2025

Human Vaccines & Immunotherapeutics
Ronald Ellis, Adam Weiss
doaj   +1 more source

From identification to accountability in private equity hospital datasets. [PDF]

Health Aff Sch
Cohen BD.
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Human vaccines and immunotherapeutics: News March 2025

Human Vaccines & Immunotherapeutics
Ronald Ellis, Adam Weiss
doaj   +1 more source

Scan Density Matters: Reproducibility of AI-Derived OCT Biomarkers in Diabetic Macular Edema. [PDF]

Transl Vis Sci Technol
Cocuzza M, Ziafati M, Lattanzio R, Midena E, Bandello F, Cicinelli MV, Current Research Directions in Ophthalmology Working Group.   +6 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Human vaccines and immunotherapeutics: News April 2025

Human Vaccines & Immunotherapeutics
Ronald Ellis, Adam Weiss
doaj   +1 more source